

DIEX Research: An internationally known clinical research company

Innovative treatments developed in Sherbrooke, Quebec, Victoriaville and Joliette

Do you know DIEX Recherche? This Sherbrooke-based company conducts high-quality clinical research with a view to finding solutions to various health problems. DIEX is in the middle of the action, currently working on the development of a plant-based vaccine against COVID-19 for Medicago, a Quebec-based pharmaceutical company.

DIEX Recherche will celebrate its 15th anniversary on May 6. The company co-founded by Suzie Talbot is involved in clinical research as part of research projects of pharmaceutical companies. Its goal: find effective treatment or prevention solutions for various health problems. This is how DIEX is committed to the fight against Alzheimer's disease, diabetes, skin conditions, cardiovascular diseases, problems related to women's health, and much more.

Relying on the expertise of its team of seasoned professionals, on the quality of the care it provides and on its scientific rigour, DIEX directs phase I to IV clinical studies that meet the requirements of its clients as well as the standards and regulations in force. Passion supports the team in its desire to surpass themselves, push the limits and exceed expectations.

DIEX's innovative fields of activity, its high-quality standards and its expertise set it apart on the clinical research scene in Canada and internationally. This is how pharmaceutical companies such as Pfizer, Sanofi, Merck, AstraZeneca and several other renowned companies call on the expertise of DIEX.

While the company was founded in Sherbrooke, it is also present in Victoriaville, Joliette and Quebec. It employs no less than 65 passionate professionals, such as nurses, graduates in pharmacology, laboratory technicians and administrators, joined by seasoned collaborators in the health field, such as family physicians, medical specialists, pharmacists, nutritionists, neuropsychiatrists, and others. DIEX brings together all of its services under one roof.

DIEX is at the head of an international network of clinical research sites

The business continues to grow. Suzie Talbot also co-founded, under the aegis of DIEX, the hyperCORE International LLP network, which brings together highly recognized clinical research sites. This grouping, established in January 2019, constitutes the second-largest network of research sites in the world, with more than 100 locations in five countries. Its unique business model combines the expertise of eleven organizations. "HyperCORE aims to accelerate research by centralizing key operations and innovative strategic partnerships with developers," explains Suzie Talbot, president. "Our main goal is to modernize the research model by bringing together the major players in the industry under one umbrella, thereby increasing efficiency exponentially."

DIEX looking for new talents, especially physicians

DIEX is constantly on the lookout for specialized expertise, and more specifically physicians from all walks of life, in order to broaden its fields of study. Any physician willing to devote even a few hours per week to research is encouraged to contact Suzie Talbot, President, at stalbot@diex.ca.

The motivations pushing physicians to do research with DIEX are varied: acquisition of new knowledge and pioneering treatment options for their patients, deepening of their knowledge in clinical research, diversification of their tasks, possibility of participating in development of new treatments and to advance the health system, etc.

Participate in a clinical study: an opportunity open to all

Health Canada requires that any new medication available has been the subject of a clinical research project. Whether or not you have a medical condition, you may be able to participate in DIEX's clinical trials. This will give you access to treatment solutions before they are available on the market, you will help advance science, and thereby improve the well-being of countless people.

How does the process work? The first step is an explanation of the treatment over the phone. You will then meet a member of the team who can answer your questions and have you sign a consent form. This form does not mean that your decision is irreversible. A participant can in fact withdraw at any time. Then comes the stage of medical tests or examinations, if necessary. Finally, if you meet the selection criteria, you can start the clinical study. Be aware that you will benefit from medical supervision throughout the study.

It is a chance to have access to innovative treatments provided by an extremely competent team, whose first principle is total respect for the patient. As Dr. Marcel Germain points out, "The participants in our research help themselves and also help society."

Anyone interested can contact DIEX at 819-346-2887 or by email at info@diex.ca.

For more information: www.diex.ca.